Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study

Bun Hee Lee, Yong Ku Kim, Sun Hwa Park

Research output: Contribution to journalArticlepeer-review

69 Citations (Scopus)


Objective: To assess the effectiveness of substituting aripiprazole for other antipsychotic drugs taken by stable schizophrenic patients suffering from antipsychotic agent-induced symptomatic hyperprolactinemia. Methods: Seven female schizophrenic patients with symptomatic hyperprolactinemia (167.6 ± 58.0 μg/L) were recruited to take part in an 8-week open label trial of aripiprazole (10-20 mg/day) as a replacement for amisulpride or risperidone. Efficacy was assessed via PANSS and CGI-I scores. Serum prolactin levels were measured at baseline, week 4, and week 8. Data were collected from November, 2004 to May, 2005. Results: At the end of weeks 4, serum prolactin levels were normalized (8.8 ± 5.5 μg/L) and hyperprolactinemic symptoms were resolved in all patients. However, aripiprazole treatment was discontinued within 6 weeks for 2 of the 7 subjects due to aggravated auditory hallucinations. Conclusion: Results from this admittedly small-scale open-label study indicate that switching to aripiprazole may be useful for resolving antipsychotic-induced hyperprolactinemia and associated symptoms.

Original languageEnglish
Pages (from-to)714-717
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number4
Publication statusPublished - 2006 Jun
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by a grant of the Korean Health 21 R&D Project, Korean Ministry of Health and Welfare (HMP-00-GN-01-0002).


  • Amisulpride
  • Aripiprazole
  • Hyperprolactinemia
  • Risperidone

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study'. Together they form a unique fingerprint.

Cite this